KEAP1 and ovarian carcinoma: Also, activation of Nrf2 pathway in ovarian cancer seems to be related to Keap1 mutations within highly conserved domains of Keap1 gene and that Nrf2 may serve as an important therapeutic target for novel drugs capable of preventing or reversing resistance to chemotherapy in ovarian cancer (Konstantinopoulos et al., 2011).